NEWS 2023.5.29 Rebirthel signs collaborative research agreement  for the development of automated cell mass culture technology  to spread allogenic T cell therapy

Rebirthel Co., Ltd. (Rebirthel) announced that it entered into a collaboration research agreement with Kyoto University and Hitachi, Ltd. (Hitachi) on January 6, 2023, for the development of automated cell mass culture technology to spread allogeneic T cell therapy^*1 for cancer treatment.
For details, please refer to the attached press release.